PT  - JOURNAL ARTICLE
AU  - Tatsuki, Onishi
AU  - Naoki, Honda
AU  - Igarashi, Yasunobu
TI  - Optimal and worst examination strategies for COVID-19
AID  - 10.1101/2021.08.31.21262868
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.31.21262868
4099  - http://medrxiv.org/content/early/2021/09/05/2021.08.31.21262868.short
4100  - http://medrxiv.org/content/early/2021/09/05/2021.08.31.21262868.full
AB  - Coronavirus disease 2019 (COVID-19) is an emerging threat to the whole world, and every government is seeking an optimal solution. However, none of them have succeeded, and they have only provided series of natural experiments. Although simulation studies seem to be helpful, there is no model that addresses the how much testing to be conducted to minimise the emerging infectious disease outbreaks. In this study, we develop a testing susceptible, infectious, exposed, recovered, and dead (testing-SEIRD) model using two discrete populations inside and outside hospitals. The populations that tested positive were isolated. Through the simulations, we examined the infectious spread represented by the number of cumulative deaths, hospitalisations, and positive tests, depending on examination strategies, testing characteristics, and hospitalisation capacity. We found all-or-none responses of either expansion or extinction of the infectious spreads, depending on the rates of follow-up and mass testing, which represent testing the people identified as close contacts with infected patients using follow-up surveys and people with symptoms, respectively. We also demonstrated that there were optimal and worst examination strategies, which were determined by the total resources and testing costs. The testing-SEIRD model is useful in making decisions on examination strategies for the emerging infectious disease outbreaks.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partly supported by the Cooperative Study Program of Exploratory Research Centre on Life and Living Systems (ExCELLS) (program Nos.18-201, 19-102, and 19-202 to H.N.), a Grant-in-Aid for Young Scientists (B) (16K16147 and 19H04776 to H.N.) from the Japan Society for the Promotion of Science (JSPS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Exempted from ethical review because no human or animal subjects or specimens are involved.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the study and its supporting information files. https://github.com/bougtoir/testing-SEIRD